On January 15, 2025, Hypha Labs, Inc. submitted a Form 8-K statement to the Securities and Exchange Commission, declaring a significant change to its corporate structure. The Nevada-based company filed a Certificate of Amendment to its Articles of Incorporation, as detailed in the Definitive Information Statement on Schedule 14C lodged on December 23, 2024.
The Certificate of Amendment outlined two fundamental revisions. Firstly, it increased the authorized shares of common stock from 250,000,000 to 880,000,000. Secondly, the authorized shares of preferred stock were elevated from 10,000,000 to 70,000,000. This amendment officially took effect on January 15, 2025.
The filing was appropriately signed by A. Stone Douglass, who serves as the Chairman, President, Chief Executive Officer, Chief Financial Officer, and Secretary of Hypha Labs, Inc. The submission met the necessary requirements of the Securities Exchange Act of 1934, underscoring the validity and compliance of the reported changes within the organization.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Hypha Labs’s 8K filing here.
Hypha Labs Company Profile
Hypha Labs, Inc, cultivates, produces, and sells psychedelic and functional mushroom in the United States. It has developed technology that quickly cultivates the mycelium root structures of psilocybin mushrooms and other functional mushroom's mycelium into a natural product. The company was incorporated in 2010 and is headquartered in Las Vegas, Nevada.
Further Reading
- Five stocks we like better than Hypha Labs
- Differences Between Momentum Investing and Long Term Investing
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- Stock Analyst Ratings and Canadian Analyst Ratings
- Micron Technology: Riding the AI Wave to Long-Term Growth